Adding Adjuvant Nivolumab Builds on Standard of Care for Res

The results of CheckMate 77T showcase the improved event-free survival for patients with resectable non–small cell lung cancer who receive nivolumab in both the neoadjuvant and adjuvant setting and may have practice-changing implications.

Related Keywords

Spain , Madrid , Anderson Tina Cascone , Tina Cascone , Division Of Cancer Medicine , Department Of Thoracic Head , Neck Medical Oncology , Cancer Medicine , Nivolumab , Nsclc , Esmo Congress ,